NM_000518.5(HBB):c.20A>T (p.Glu7Val)

For the canonical sickle variant HBB c.20A>T (p.Glu7Val), ex vivo CRISPR editing that raises fetal hemoglobin is the most clinically validated gene-editing strategy currently available. The therapeutic effect does not repair the HBB codon directly, but it is directly relevant to this genotype because it reduces HbS polymerization pressure by re-inducing HbF in autologous erythroid cells.

ClinVar lists HBB c.20A>T as Pathogenic and this variant is the molecular basis of classic sickle cell disease. In the phase 3 CLIMB SCD-121 study of exagamglogene autotemcel, severe sickle cell disease patients treated with CRISPR-Cas9 edited autologous hematopoietic stem cells had marked reduction of vaso-occlusive crises and durable clinical benefit (PMID:38661449). A 2025 review of gene therapies for hemoglobinopathies also places BCL11A enhancer editing among the leading clinically validated approaches for sickle cell disease (PMID:41223813). Because the mechanism is HbF reactivation rather than allele-specific repair, the strategy is robust to the exact HbS codon context and avoids needing efficient in vivo delivery to all erythroid precursors.

This is not a direct correction of p.Glu7Val, so edited patients still carry the pathogenic HBB allele. The approach requires myeloablative conditioning, autologous stem-cell collection, and specialized transplant infrastructure, which materially limits scalability and raises toxicity concerns. The evidence base is strongest for severe disease populations treated at expert centers, and long-term durability beyond the currently reported follow-up windows still needs continued surveillance. It also does not answer whether direct in vivo correction of HBB c.20A>T will ever outperform HbF reactivation on risk-benefit grounds.